Infirst Healthcare Limited

Peptcell Limited

Lipoxen Technologies Incorporated

Biocopea Limited

Infirst Helathcare Limited

Wilson Romero Caparros-Wanderley

Gregory Alan Stoloff

Robin Mark Bannister

John Brew

Suzanne Jane Dilly

Olga Pleguezuelos Mateo

Gemma Szucs

Peter Laing

Andrew David Bacon

Gregory Gregoriadis

Gregory Gregoriados

Richard Robert Reiley

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Compositions and methods for treating chronic inflammation and inflammatory diseases

The present specification discloses recombinant nucleic acid constructs encoding an immunogenic multiepitope polypeptide comprising two or more polypeptides, recombinant nucleic acid constructs encoding at least two epitopes from two or more internal proteins of influenza virus, compositions comprising such recombinant nucleic acid constructs and methods of eliciting a T cell immune response against an influenza virus in a vertebrate using such recombinant nucleic acid constructs and compositions.

Influenza peptides and compositions

The present specification discloses pharmaceutical compositions formulated as a suspension for oral administration, the suspension comprising solid particles of a non-steroidal anti-inflammatory drug (NSAID) in an oil carrier comprising one or more free fatty acids, a glycerolipid, and a phospholipid as well as methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.

Oral suspensions comprising a non-steroidal anti-inflammatory drug (NSAID)

The present specification disclosesantigens, immunogenic compositions and medicaments comprising suchantigens, methods and uses for suchantigens and immunogenic compositions for treating a-based disease.

Chagas antigens and antibodies and compositions, methods and uses thereof

Peptide sequences and compositions

Provided is a polypeptide composition comprising one or more polypeptides, which polypeptides are immunogenic in a vertebrate such that they cause the vertebrate to produce immune system cells capable of recognizing at least one epitope from an arthropod saliva protein fraction, wherein the arthropod saliva protein fraction has a mass of 40 kDA or less, and wherein the polypeptides are selected independently from:

Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-6, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-6 that has the same length as the epitope: wherein, the polypeptide is immunogenic in a vertebrate expressing a major histocompatibility complex (MHC) allele, and wherein the polypeptide is not a complete influenza virus protein.

The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.

Growing community of inventors

London, United Kingdom

Wilson Romero Caparros-Wanderley